曲帕替平 | 27574-24-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 中文名称: 曲帕替平
• 英文名称: 3-(6H-dibenzo[b,e]thiepin-11-ylidene)-8-methyl-nortropane
• 英文别名: 3-(6H-benzo[c][1]benzothiepin-11-ylidene)-8-methyl-8-azabicyclo[3.2.1]octane
• CAS: 27574-24-9
• 化学式: C₂₂H₂₃NS
• 分子量: 333.497
• InChiKey: JOQKFRLFXDPXHX-UHFFFAOYSA-N

物化性质

• 沸点：
  493.1±45.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  24
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

制备方法与用途

托伐他平是一种抗胆碱能的毒蕈碱拮抗剂，可以作为抗帕金森病药物使用[1]。此外，它还能用于缓解因抗精神病药物导致的锥体外系综合征[2]。

文献信息

• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143143A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• Fluorinated cyclopropane analogs of glutamic acid
  申请人：Institut National des Sciences Appliquées de Rouen (INSA)

  公开号：EP2279997A1

  公开（公告）日：2011-02-02

  The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt, a stereoisomer or a mixture in all proportions of stereoisomers thereof, in particular a mixture of enantiomers, such as a racemic mixture, wherein R represents a (C1-C6)alkanediyl or (C1-C6)alkenediyl group, optionally substituted by one or more groups chosen among an halogen atom, ORa, SRb, NRcRd, PO(ORe)(ORf), CO2Rg, SO2Rh SO3Ri, PO(OH)(CH(OH)Rk), CN, N3 and NH-C(=NH)NH2, with Ra, Rb, Rc and Rd, representing, independently of each other, an hydrogen atom, a (C1-C6)alkyl group or a -CO-(C1-C6)alkyl group, Re, Rf, Rg, Rh and Ri representing, independently of each other, an hydrogen atom or a (C1-C6)alkyl group, and Rk representing an aryl or heteroaryl group, said group being optionally substituted by one or more groups selected from an halogen atom and NO2, as well as to the use thereof and to a process for preparing such a compound, to a pharmaceutical composition containing it and to synthesis intermediates.

  本发明涉及以下式（I）的化合物：或其药学上可接受的盐、立体异构体或其立体异构体的各种比例的混合物，特别是对映体的混合物，如消旋混合物，其中R代表（C1-C6）烷二基或（C1-C6）烯二基基团，可选地被一个或多个在卤原子、ORa、SRb、NRcRd、PO（ORe）（ORf）、CO2Rg、SO2Rh、SO3Ri、PO（OH）（CH（OH）Rk）、CN、N3和NH-C（=NH）NH2中选择的基团之一取代，其中Ra、Rb、Rc和Rd分别独立地代表氢原子、（C1-C6）烷基或-CO-（C1-C6）烷基基团，Re、Rf、Rg、Rh和Ri分别独立地代表氢原子或（C1-C6）烷基基团，Rk代表芳基或杂环基团，所述基团可选地被一个或多个从卤原子和NO2中选择的基团取代，以及其用途、制备这种化合物的方法、含有它的药物组合物和合成中间体。
• [EN] FLUORINATED CYCLOPROPANE ANALOGS OF GLUTAMIC ACID<br/>[FR] ANALOGUES CYCLOPROPANIQUES FLUORÉS DE L'ACIDE GLUTAMIQUE
  申请人：INST NAT SCIENCES APPLIQ

  公开号：WO2011009947A1

  公开（公告）日：2011-01-27

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a mixture in all proportions of stereoisomers thereof, in particular a mixture of enantiomers, such as a racemic mixture, wherein R represents a (C1-C6)alkyl or (C1-C6)alkenyl group, optionally substituted by one or more groups chosen among an halogen atom, ORa, SRb, NRcRd, PO(ORe)(ORf), CO2Rg, SO2Rh SO3R1, P0(0H)(CH(0H)Rk), CN, N3 and NH- C(=NH)NH2, with Ra, Rb, Rc and Rd, representing, independently of each other, an hydrogen atom, a (C1-C6)alkyl group or a -CO-(C1-C6)alkyl group, Re, Rf, Rg, Rh and R1 representing, independently of each other, an hydrogen atom or a (C1-C6)alkyl group, and Rk representing an aryl or heteroaryl group, said group being optionally substituted by one or more groups selected from an halogen atom and NO2, as well as to the use thereof and to a process for preparing such a compound, to a pharmaceutical composition containing it and to synthesis intermediates.

  本发明涉及一种具有式(I)的化合物或药学上可接受的盐，其立体异构体或其立体异构体的各种比例的混合物，特别是对映体的混合物，如消旋混合物，其中R代表(C1-C6)烷基或(C1-C6)烯基基团，可选地被一个或多个在卤素原子、ORa、SRb、NRcRd、PO(ORe)(ORf)、CO2Rg、SO2Rh、SO3R1、P0(0H)(CH(0H)Rk)、CN、N3和NH-C(=NH)NH2中选择的基团之一取代，其中Ra、Rb、Rc和Rd分别独立地表示氢原子、(C1-C6)烷基或-CO-(C1-C6)烷基基团，Re、Rf、Rg、Rh和R1分别独立地表示氢原子或(C1-C6)烷基基团，Rk表示芳基或杂环芳基基团，所述基团可选地被一个或多个从卤素原子和NO2中选择的基团取代，以及其用途、制备这种化合物的方法、含有它的药物组合物和合成中间体。
• [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS UTILISÉS COMME MODULATEURS ALLOSTÉRIQUES DE RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE DU GROUPE II
  申请人：MAVALON THERAPEUTICS LTD

  公开号：WO2018206820A1

  公开（公告）日：2018-11-15

  The present invention provides novel heterocyclic compounds of the general formula (I), including novel compounds of formula (la), and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) or (la) and the pharmaceutical compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. The compounds of formula (I) or (la) can act as modulators of nervous system receptors sensitive to glutamate, in particular as modulators of metabotropic glutamate receptors (mGluRs), which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. The present invention further provides compounds of formula (I) or (la) that are modulators of metabotropic glutamate receptors (mGluRs), particularly positive allosteric modulators of mG!uRs, and more specifically positive allosteric modulators of mGluR3.

  本发明提供了一般式(I)的新颖杂环化合物，包括一般式(la)的新化合物，以及含有它们的药物组合物。此外，提供了一般式(I)或(la)的化合物和含有它们的药物组合物，用于治疗和/或预防与改变谷氨酸能信号和/或功能相关的疾病，以及那些可能受到哺乳动物谷氨酸水平或信号改变影响的疾病。一般式(I)或(la)的化合物可以作为对谷氨酸敏感的神经系统受体的调节剂，特别是代谢型谷氨酸受体(mGluRs)的调节剂，这使它们特别适用于治疗和/或预防急性和慢性神经和/或精神障碍。本发明还提供了一般式(I)或(la)的化合物，它们是代谢型谷氨酸受体(mGluRs)的调节剂，特别是mGluRs的正向变构调节剂，更具体地说是mGluR3的正向变构调节剂。